34% of FDA approved drugs target G protein coupled receptors (GPRCs). The dopamine D2 receptor (D2R) is currently targeted by all applied antipsychotic drugs. Understanding drug-binding kinetics and the underlying molecular mechanisms is important for the development of new ligands targeting D2R. In the current project, antipsychotic drugs will be docked to crystal structures of the D2R, followed by molecular dynamics simulations to investigate the ligand-binding poses. Next, umbrella sampling will be used to evaluate the stability of the binding poses. The results may elucidate the crucial D2R residues that mediate antipsychotic binding. Additionally, the in silico findings may guide prospective experimental sutdies using point- mutated D2rs.